3Thoma R, Loffier B, Stihle M, et al.Structural basis of pro- line-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV [J]. Structure, 2003,11(8) : 947.
4Hartel S, Gossrau R, Hanski C, et al.Dipeptidyl peptidase IV in rat organs: comparison of immunohis to chemistry and activity histochemistry[J]. Histochemistry, 1988, 89 (2):151.
5Boonacker E, van Noorden CJ.The multifimctional or mo- omlighting protein CD26/DPp- IV [J]. Eur J Cell Biol, 2003,82(2):53.
6Baenett A. DPP-4 inhibitor sandtheir potential role in the management of type 2 diabetes[J].Int J Clin Pratt, 2006, 60(11):1 454.
7Bohannon N.Overview of the gliptin class (dipeptidyl pep- tidase-4 inhibitors) in clinical practice[J]. Postgrad Med, 2009,121(1):40.
8Flock G, Baggio LL, Longuet C, et al. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulin- otropic polypeptide are essential for the sustained meta- bolic actions of vildagliptin in mice[J].Diabetes, 2007, 56 (12) :3 006.
9Hansotia T, Drucker DJ.GIP and GLP-1 as incrtin hormo- nes: lessons from single and double incretin receptor knockout mice[J].Regul Popt, 2005,128(2) : 125.
10Zinman B, Hoogwerf B J, Duran Chrcia S, et al.The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial[J].Ann In-tern Meal,2007,146(7) :477.
